MedTrace Logo

Collection of Maternal Blood Samples for Development of Non-invasive Prenatal Diagnostic Testing

NCT01546324 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2013-08-12

No results posted yet for this study

Summary

The purpose of this study is to collect blood samples from pregnant women who achieved pregnancy following in-vitro fertilization (IVF) with Natera's preimplantation aneuploidy screening (with or without single gene gene testing). These samples will be used for test development of non-invasive prenatal diagnostic testing.

Conditions

  • Pregnancy Following IVF With PGS/PGD

Interventions

PROCEDURE

Blood draw

Maternal blood draw at approximately 8-17 weeks gestation.

Sponsors & Collaborators

  • Natera, Inc.

    lead INDUSTRY

Principal Investigators

  • Matthew Rabinowitz, PhD · CEO, Natera, Inc

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2012-05-31
Completion
2013-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01546324 on ClinicalTrials.gov